Biosimilars, the journey has begun
According to the European Medicine Agency, a “biosimilar” is a biological medicinal product that contains a version of the active substance of an original biological medicinal product (reference or innovative medicinal product) that has been authorized in the European Economic Area. The similarity t...
Saved in:
| Main Authors: | Alba Martos-Rosa, Juan Enrique Martínez-de la Plata, Jose Antonio Morales-Molina, Anna Fayet- Pérez, Pedro José Acosta-Robles |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2015-01-01
|
| Series: | Farmacia Hospitalaria |
| Subjects: | |
| Online Access: | http://www.aulamedica.es/fh/pdf/8789.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evaluation of rheumatologists’ knowledge of biosimilars
by: Thayane Furtado Rolim Lima, et al.
Published: (2025-07-01) -
Biosimilars: presumption of guilt
by: Marina Vladimirovna Shestakova, et al.
Published: (2011-12-01) -
Biosimilars: development and investigation using achievements in modern biotechnology
by: R. R. Niyazov, et al.
Published: (2021-02-01) -
Safety of Switching from a Reference Biologic to Its Biosimilar: A Systematic Review and Meta-Analysis
by: Sarah Saad Aljahili, et al.
Published: (2025-02-01) -
Biologics and biosimilars in musculoskeletal diseases: addressing regulatory inconsistencies and clinical uncertainty
by: Lauren N. McGrath, et al.
Published: (2025-07-01)